Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA(®) Trial

INTRODUCTION: We evaluated the cost-effectiveness of linagliptin in Japan by estimating the lifetime outcome based on clinical event rates from the Asian subpopulation of the CARMELINA trial. In CARMELINA, linagliptin added to standard of care (SoC) versus SoC demonstrated noninferiority with regard...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Ther
Autors principals: Watada, Hirotaka, Sakamaki, Hiroyuki, Yabe, Daisuke, Yamamoto, Fumiko, Murata, Tatsunori, Hanada, Keigo, Hirase, Tetsuaki, Okamura, Tomoo
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7376765/
https://ncbi.nlm.nih.gov/pubmed/32557283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-020-00852-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars